Trials / Recruiting
RecruitingNCT06182696
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- OriCell Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM
Detailed description
This is a Phase I and Phase II, open-label, multi-center study to assess the safety, pharmacokinetics, and efficacy of GPRC5D directed chimeric antigen receptor modified T cells injection (OriCAR-017) in n patients with relapsed and/or refractory multiplemyeloma (R/RMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OriCAR-017 | GPCRC5D-directed chimeric antigen receptor modified T cells |
Timeline
- Start date
- 2023-10-26
- Primary completion
- 2026-11-30
- Completion
- 2028-08-31
- First posted
- 2023-12-27
- Last updated
- 2024-05-31
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06182696. Inclusion in this directory is not an endorsement.